TABLE 1: Characteristics of patient 1 and 2. ADxE, cytarabine,
liposomal daunorubicin, etoposide; haM, high-dose
cytarabine/mitoxantrone; AI/2 CDA, cytarabine/
idarubicin/2-chloro-2-deoxyadenosine; HAE, high-dose
cytarabine/etoposide; 6-TG, 6-thioguanine; AraC, cytarabine; FLAG-Ida,
fludarabine, high-dose cytarabine, G-CSF, and idarubicin; ATG,
anti-thymocyte globulin; ADE, cytarabine, daunorubicin, etoposide; AE,
cytarabine, etoposide; AM, cytarabine, mitoxantrone. *MRD not evaluable
due to hypocellular marrow.
FIGURE 1 LEGEND:
FIGURE 1: Cardiac Function vs Time Post-GO for Patients 1 and 2A. Left ventricle ejection fraction (LVEF) as measured by
M-Mode for Patient 1 (blue circles) and Patient 2 (red squares) vs time
in days from gemtuzumab ozogamicin (GO) with clinical highlights.B. LV systolic function (LVSF) measurements over time measured
with M-Mode. C. LV diastolic volume in milliliters (mL) over
time. D. LV Mass z-score over time. E. LV Mass Index
expressed as grams (g)/height (ht)2.7. F&G.LV transmitral early peak velocity (E) to early diastolic mitral annulus
velocity (e’ ) ratios. E/e’ ratios >14 are one
feature of diastolic dysfunction. H. B-Natriuretic Peptide
measurements over time in picograms(pg)/ml